Recent advances in molecular biology suggest that in vivo manipulation of gene products may favorably alter clinical outcome in patients with congestive heart failure or vascular disease. As part of the University of Pittsburgh's specific genes that play a pathophysiologic role in myocardial failure and failure of arteriovenous shunts. While it is hypothesized that these novel therapies will alter the phenotypic expression of specific target cells (e.g., failing cardiac myocytes, vascular cells in arteriovenous shunts), the effects of these genes on other non- targeted cells are unknown. Accordingly, it is mandatory that closely supervised evaluation of enrolled patients be performed to not only assess the anticipated favorable outcome but to ensure that there are no unexpected side effects that may outweigh the benefits of these therapies. The primary goal of the clinical research core of this RFA is to provide independent oversight of both of the proposed clinical trials to ensure that potential adverse events are identified and appropriately reported to the study's independent Data and Safety Monitoring, the University of Pittsburgh Biomedical IRB, the National Institutes of Health and, when appropriate, the US Food and Drug Administration.
The specific aims of the core are: 1. To ensure that clinical gene interventions in this project adhere to all local and federally-mandated scientific and bioethic agencies. 2. To audit and investigate all adverse and significant adverse event associated with the proposed trials for quality assurance. 3. To form an independent data and safety monitoring board which will be responsible for interim analysis of safety and outcome parameters to ensure that adverse events do not compromise patient safety. To ensure patient safety, which is the highest priority of these studies, the clinical core will be responsible for (1) oversight of reporting of adverse events, (2) quality assurance, (3) interim analysis of adverse events and patient outcome, and (4) formation of an independent data and safety monitoring board which will evaluate the incidence of adverse events and patient outcomes to determine whether the studies meet pre-specified safety criteria. To perform these functions, the clinical core staff will be administratively, financially, and scientifically independent of the investigators and staff of the molecular biology and clinical trial projects. The independence of the clinical core has been ensured by the PI of the overall project (Dr. Joe Glorioso) and the Dean of the University of Pittsburgh Medical School (Dr. Arthur Levine) who have granted the clinical core PI (Dr. Steven Reis) complete autonomy and have empowered him with the right to withdraw active therapy form specific patients and to terminate the clinical studies should they meet pre- specified safety criteria.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HL066949-03S1
Application #
6668349
Study Section
Special Emphasis Panel (ZHL1)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
$292,370
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Laemmle, Lillian L; Cohen, Justus B; Glorioso, Joseph C (2016) Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells. Open Biotechnol J 10:248-257
Goins, William F; Hall, Bonnie; Cohen, Justus B et al. (2016) Retargeting of herpes simplex virus (HSV) vectors. Curr Opin Virol 21:93-101
Zhu, Xiaodong; McTiernan, Charles F; Rajagopalan, Navin et al. (2012) Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression. Hum Gene Ther 23:722-32
Ramani, Ravi; Nilles, Kathleen; Gibson, Gregory et al. (2011) Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 4:24-31
Yoshimura, Naoki; Kato, Ryuichi; Chancellor, Michael B et al. (2010) Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther 10:1305-14
Frampton Jr, Arthur R; Uchida, Hiroaki; von Einem, Jens et al. (2010) Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Vet Microbiol 141:12-21
Kato, R; Wolfe, D; Coyle, C H et al. (2009) Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther 16:26-33
Peng, Fuwang; Dhillon, Navneet K; Yao, Honghong et al. (2008) Mechanisms of platelet-derived growth factor-mediated neuroprotection--implications in HIV dementia. Eur J Neurosci 28:1255-64
Cardinal, Jon; Klune, John Robert; Chory, Eamon et al. (2008) Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery 144:125-32
Li, Han; Baskaran, Rajasekaran; Krisky, David M et al. (2008) Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology 375:13-23

Showing the most recent 10 out of 40 publications